Loading...
XNASADMA
Market cap4.39bUSD
Jan 08, Last price  
18.56USD
1D
1.48%
1Q
9.11%
Jan 2017
262.50%
IPO
117.58%
Name

ADMA Biologics Inc

Chart & Performance

D1W1MN
XNAS:ADMA chart
P/E
—
P/S
16.99
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.73%
Rev. gr., 5y
72.34%
Revenues
258m
+67.59%
000001,118,1183,067,5775,915,5457,177,63310,661,03722,760,56016,985,29029,349,08342,219,78380,942,625154,079,692258,214,999
Net income
-28m
L-66.85%
-29,687,000-24,891,000-20,009,000-20,526-26,460-7,301,313-15,527,246-16,813,163-17,969,930-19,515,151-43,758,975-65,743,445-57,045,374-87,605,086-84,452,877-85,183,323-28,239,000
CFO
9m
P
-23,615,000-19,005,000-24,459,000-19,676-29,000-6,903,795-10,887,154-14,704,910-15,418,404-18,268,973-37,271,774-62,678,682-76,193,504-102,002,958-112,368,982-59,508,2578,800,000
Earnings
Feb 26, 2025

Profile

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
URL
https://www.admabiologics.com/
IPO date
Oct 17, 2013
Employees
617
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
258,215
67.59%
154,080
90.36%
Cost of revenue
172,573
122,428
Unusual Expense (Income)
NOPBT
85,642
31,651
NOPBT Margin
33.17%
20.54%
Operating Taxes
19,279
Tax Rate
60.91%
NOPAT
85,642
12,372
Net income
(28,239)
-66.85%
(85,183)
0.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,415)
61,746
BB yield
0.14%
-8.04%
Debt
Debt current
863
905
Long-term debt
151,197
165,147
Deferred revenue
1,690
1,833
Other long-term liabilities
2,107
1,850
Net debt
100,708
79,531
Cash flow
Cash from operating activities
8,800
(59,508)
CAPEX
(4,771)
(13,911)
Cash from investing activities
(4,981)
(13,911)
Cash from financing activities
(38,989)
108,852
FCF
79,538
(15,843)
Balance
Cash
51,352
86,522
Long term investments
Excess cash
38,441
78,818
Stockholders' equity
(506,233)
(477,994)
Invested Capital
786,654
788,095
ROIC
10.88%
1.71%
ROCE
30.54%
10.21%
EV
Common stock shares outstanding
223,977
197,875
Price
4.52
16.49%
3.88
175.18%
Market cap
1,012,377
31.86%
767,755
290.11%
EV
1,113,085
847,285
EBITDA
93,974
38,765
EV/EBITDA
11.84
21.86
Interest
25,027
19,279
Interest/NOPBT
29.22%
60.91%